共查询到20条相似文献,搜索用时 0 毫秒
1.
Extramedullary leukemia in children with acute myeloid leukemia: A population‐based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO)
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Heidi Kristine Støve Julie Damgaard Sandahl Jonas Abrahamsson Peter H. Asdahl Erik Forestier Shau‐Yin Ha Kirsi Jahnukainen Ólafur G. Jónsson Birgitte Lausen Josefine Palle Bernward Zeller Henrik Hasle 《Pediatric blood & cancer》2017,64(12)
1 Background
The prognostic significance of extramedullary leukemia (EML) in childhood acute myeloid leukemia is not clarified.2 Procedure
This population‐based study included 315 children from the NOPHO‐AML 2004 trial.3 Results
At diagnosis, 73 (23%) patients had EML: 39 (12%) had myeloid sarcoma, 22 (7%) had central nervous system disease, and 12 (4%) had both. EML was associated with young age (median age: 2.6 years), a high white blood cell count (median: 40 × 109/l), M5 morphology (40%), and 11q23/MLL (KMT2A) rearrangements (34%). No patient received involved field radiotherapy. Five‐year event‐free survival did not differ significantly between the EML and the non‐EML patients (54% vs. 45%, P = 0.57), whereas 5‐year overall survival (OS) was significantly lower in the EML group (64% vs. 73%, P = 0.04). The risk of induction death was significantly higher for EML patients (8% vs. 1%, P = 0.002). There was a trend toward a lower risk of relapse for EML patients (5‐year cumulative incidence of relapse 33% vs. 49%, P = 0.16). Traumatic lumbar puncture did not adversely affect survival in this cohort.4 Conclusions
EML was associated with increased risk of induction death impacting the OS. No patients relapsed at the primary site of the myeloid sarcoma despite management without radiotherapy. 相似文献2.
R Nygaard P J Moe H Brincker N Clausen R Nyman M Perkki? M E Eilertsen O J Johansen M V?re L Brinch 《Medical and pediatric oncology》1989,17(1):45-47
Seven late relapses of acute lymphoblastic leukemia occurring 5.5 to 12.3 years after cessation of therapy are reported in 986 patients who had discontinued treatment for leukemia acquired before the age of 15. The study covers patients from the five Nordic countries. Of the 434 patients with ALL who had passed 5 years of follow-up without recurrence, seven have subsequently relapsed so far; an estimated cumulative proportion of 6.9% within the 10 years. In addition, we report a girl 15.9 years old at diagnosis who relapsed 7.3 years after cessation of therapy. These findings confirm that "cure" of acute lymphoblastic leukemia treated in the 1970s cannot be considered definite, even 5 years after discontinuation of therapy. 相似文献
3.
G Gustafsson G Berglund S Garwicz H Hertz G Jonmundsson P J Moe T T Salmi M Seip M A Siimes M Yssing 《Acta paediatrica Scandinavica》1989,78(1):104-109
Two hundred and thirty children with standard risk acute lymphoblastic leukemia (ALL) were diagnosed during a period of 3 years from July 1, 1981 to June 30, 1984 in the five Nordic countries. Criteria for standard risk ALL were age above 2.0 and below 10 years, WBC less than or equal to 20 x 10(9)/l, no evidence of CNS-involvement, mediastinal mass or T- or B-cell leukemia. The children were treated without prophylactic CNS irradiation, the majority (200 patients) according to two treatment programs. Follow-up of the entire group after a minimum of 30 months showed 64% of the children living in complete continuous remission with a probability of event-free survival of 0.60. The treatment results are not entirely satisfactory and intensification of therapy is required. A subgroup of patients with WBC between 10 and 20 x 10(9)/l and with adverse prognosis was identified, justifying a change of the present criteria for risk grouping. 相似文献
4.
G Gustafsson S Garwicz H Hertz G Johanesson G Jonmundsson P J Moe T Salmi M Seip M A Siimes M Yssing 《Acta paediatrica Scandinavica》1987,76(5):781-788
Six hundred and fifty-six children with acute lymphoblastic leukemia (ALL) have been diagnosed in the five Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) during the period from July 1981 through June 1985. Annual incidence of ALL was 3.6/100,000 children aged less than 15 years, with an incidence for males of 3.8 and for females of 3.4 respectively. Half of the children were younger than 5 years of age at diagnosis, with a peak incidence between 2-3 years of age. The leukemias were classified as Standard Risk (SR), Intermediate Risk (IR) or High Risk (HR) leukemia according to prognostic criteria at diagnosis. The remission rate was 95%. In children greater than or equal to 1 year of age with non-B-cell ALL at diagnosis, the Event-Free Survival (EFS) was 0.58; 0.65 for SR-children, 0.51 for IR-children and 0.52 for HR-children. WBC count at diagnosis was the most important prognostic factor and a WBC count of 11-20 X 10(9)/l was associated with the worst prognosis of all WBC values (EFS = 0.30), independent of other prognostic factors. Male sex was the second most important adverse prognostic criterion. The follow-up in January 1986 (observation time 6-54 months), showed that 442 of the 656 children (67%) were in complete continuous remission. The total results indicate a possibility to improve the prognosis for most of the risk groups of ALL with a more intensive treatment. 相似文献
5.
6.
Jeong DC Chung NG Kang HJ Koo HH Kook H Kim SK Kim SY Kim HS Kim HM Park KD Park SK Park JS Park JE Park HJ Park YS Seo JJ Sung KW Shin HY Ahn HS Ryu KH Ryu KH Yoo ES Lyu CJ Lee KS Lee KC Lee SY Lee YH Lim YT Lim YJ Jung HL Cho B Choi YM Hah JO Hwang TJ Kim HK 《Journal of pediatric hematology/oncology》2011,33(3):172-178
7.
8.
U B Graubner J Boos U Creutzig W D?rffel M Lakomek C Niemeyer M Schrappe H J Spaar B H Belohradsky 《Klinische P?diatrie》1999,211(4):347-352
Infections in disease- and/or chemotherapy-related neutropenia are major, often emergency-type problems in the treatment of pediatric oncology patients and explain the ongoing discussion about antiinfectious prophylaxis. The different aspects of prophylaxis and an overview on the literature are presented. Antiinfectious prophylaxis in pediatric oncology includes the following issues: 1. General aspects such as information for patients and parents on neutropenia and risk of infectious diseases and indication and management of reverse isolation and barrier isolation; 2. antibacterial prophylaxis with oral non-absorbable and oral absorbable antibiotics; 3. Pneumocystis carinii (Pc) prophylaxis; 4. antifungal prophylaxis to prevent disseminated candidiasis and aspergillosis; 5. antiviral prophylaxis, especially varicella-zoster-virus (VZV) post-exposure prophylaxis and cytomegalovirus (CMV) prophylaxis; 6. immunoglobulins and hematopoietic growth-factors (HGF); 7. active immunization. An evaluation of those measures leads to the following conclusions: A major controversy exists regarding antibacterial and antifungal prophylaxis. Probably not effective are the use of reverse isolation and of oral, non-absorbable antibiotics. Oral absorbable antibiotics, antifungal prophylaxis using fluconazole and amphotericin B and the use of hematopoietic growth factors are likely to be effective. Clearly effective are strict hand-washing procedures, Pc and CMV prophylaxis and passive vaccination against VZV in case of VZV exposure of a seronegative patient. 相似文献
9.
10.
H. Schroeder S. Garwicz J. Kristinsson M. A. Siimes F. Wesenberg G. Gustafsson 《Pediatric blood & cancer》1995,25(5):372-378
This study reports the outcome after relapse of acute lymphoblastic leukemia (ALL) in a population-based study of 809 children over 1 year of age diagnosed July 1981 through June 1986 and with non-B acute lymphoblastic leukemia in the five Nordic countries. By January 1994, 315 children had suffered at least one relapse. The bone marrow was involved in 216 cases. There were 69 isolated CNS relapses, 25 isolated testicular recurrences and five relapses in other extramedullary sites. Of the 315 children with relapse, 94 are still in a second complete remission 12–138 (median: 78) months after relapse. The overall probability of a second event free survival (P-2.EFS) and survival after relapse was 0.28 and 0.33 respectively. The probability of remaining in second remission at 11 years was significantly correlated to the duration of first remission (P < 0.001), the site of relapse (P < 0.001) and gender (P = 0.004). The P-2.EFS for early, intermediate, and late bone marrow involved relapses were 0.08, 0.19, and 0.50 respectively. For early, intermediate and late isolated CNS relapses the P-2.EFS were 0.21, 0.38 and 0.61, respectively. The P-2.EFS for boys with isolated testicular relapses was 0.69. Girls with isolated CNS relapse (P < 0.001) and with bone marrow involved relapse (P = 0.04) had a significantly better prognosis than boys. Children with initial high risk criteria, especially T-ALL and mediastinal mass who relapsed, had a very poor prognosis. Conclusion: In this population-based study, about 30% of children with ALL obtained a long second remission and possible cure. © 1995 Wiley-Liss, Inc. 相似文献
11.
P J Moe 《Acta paediatrica Scandinavica》1978,67(2):145-149
A survey is presented of 160 children from the Nordic countries who had their antileukemic therapy discontinued prior to November 1976. Twenty-seven of the 160 cases (17%) had suffered a relapse before May, 1977. Sixty-nine cases had their therapy stopped in the first ten months of 1976. All cases have been reported as acute lymphocytic leukemia. Different types of therapy schedules have been used. Thirty-five cases in sustained remission for more than 3 years without cessation of therapy are also included in the report, seventeen of whom had relapsed while still on therapy. Central nervous system or testicular relapse occurred in 21 of the total 44 cases who relapsed after three or more years of continuous remission, and whether they were on therapy or not. 相似文献
12.
Sanjeev A. Vasudevan Tu‐Anh N. Ha Huirong Zhu Todd E. Heaton Michael P. LaQuaglia Joseph T. Murphy Wesley E. Barry Catherine Goodhue Eugene S. Kim Jennifer H. Aldrink Stephanie F. Polites Harold J. Leraas Henry E. Rice Elisabeth T. Tracy Timothy B. Lautz Riccardo A. Superina Andrew M. Davidoff Max R. Langham Andrew J. Murphy Andreana Bütter Jacob Davidson Richard D. Glick James Grijalva Kenneth W. Gow Peter F. Ehrlich Erika A. Newman Dave R. Lal Marcus M. Malek Annie Le‐Nguyen Nelson Pich David H. Rothstein Scott S. Short Rebecka Meyers Roshni Dasgupta 《Pediatric blood & cancer》2020,67(9)
13.
14.
15.
16.
17.
Johnnie K. Bass AuD Jie Huang MS Arzu Onar‐Thomas PhD Kay W. Chang MD Shaum P. Bhagat PhD Murali Chintagumpala MD Ute Bartels MD Sridharan Gururangan MRCP Tim Hassall MBBS FRACP John A. Heath PhD Geoffrey McCowage MB BS Michael J. Fisher MD Giles Robinson MD Alberto Broniscer MD Amar Gajjar MD James G. Gurney PhD 《Pediatric blood & cancer》2014,61(4):601-605
18.
P Blouin A Auvrignon A Pagnier I Thuret G Antoni B Bader-Meunier F Le Deist P Chastagner N Aladjidi I Pellier Y Bertrand C Behar J Landmann-Parker G Leverger Y Perel 《Archives de pédiatrie》2005,12(11):1600-1607
Evans' Syndrome (ES) is defined as the combination of immune thrombocytopenia (ITP) and autoimmune haemolytic anemia (AIHA), in the absence of any known underlying etiology. Pathophysiology, epidemiology and outcome remain unclear. POPULATION: Thirty-six children (20 male, 16 female), who were diagnosed in the SHIP french centres (Société d'hématologie et d'immunologie pédiatrique) between 1990 and 2002 with ES, were included in this retrospective study. RESULTS: Median age at diagnosis was 4 years. In 21 children, ES occurred in the setting of consanguinity, family history of autoimmune/inflammatory disease, associated autoimmune disorder or immunoregulatory abnormalities (serum imunoglobulins, peripheral blood lymphocytes subsets, low level of the C3-C4 complement components, nuclear antibodies). Several successive treatments were used in this serie (median: 3, range: 0-10) including corticosteroid therapy (35/36), intravenous immunoglobulins (32/36), immunosuppressive agents (14/36), splenectomy (9/36) and anti CD 20 monoclonal antibodies (6/36). Patients with a low level of serum immunoglobulins were more often non-responders to corticosteroidtherapy/intravenous immunoglobulins and required more frequently further therapy (P=0.03). Three patients died (intracranial bleeding, N=2, Guillain-Barre syndrome; N=1). CONCLUSION: ES was a severe, life-threatening disease, requiring aggressive immunosuppressive therapy in as many as half the patients. Our forthcoming study aims to (i) describe homogeneously-studied and prospectively-analysed cohort of childhood ES, (ii) separate ES from specific immune deficiency (especially fas gene mutations), generalised autoimmune/inflammatory disorders and genetic diseases, (iii) identify well-defined ES subsets, (iv) establish prognostic factors and optimal treatment within these subsets. 相似文献
19.
20.
Jones DP Spunt SL Green D Springate JE;Children's Oncology Group 《Pediatric blood & cancer》2008,51(6):724-731
Improvements in childhood cancer therapy have led to increasing numbers of long-term survivors. These survivors are at risk for a variety of late effects due to the disease itself, treatment exposures (surgery, chemotherapy, and radiotherapy), underlying medical problems, and health behaviors. The COG LTFU Guidelines are risk-based, exposure-related recommendations for the identification and management of late effects due to therapies utilized in the treatment of childhood cancer, and are designed for asymptomatic survivors presenting for routine medical follow-up 2 or more years after completion of cancer therapy. The COG Guidelines Task Force on Urinary Tract Complications conducted an extensive review of the medical literature via MEDLINE. Specific treatment exposures which were reviewed include nephrectomy, chemotherapy regimens known to be nephrotoxic (cisplatin, carboplatin, ifosfamide, and methotrexate), and renal irradiation. Literature sources were ranked according to the strength of evidence and are cited in the review. This review summarizes the literature that supported the recommendations for cancer survivors at risk for nephrotoxicity previously outlined in the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers (COG LTFU Guidelines). 相似文献